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Abstract Gaucher disease is caused by a deficiency of the
lysosomal enzyme glucocerebrosidase (acid β-glucosidase),
with consequent cellular accumulation of glucosylceramide
(GL-1). The disease is managed by intravenous admin-
istrations of recombinant glucocerebrosidase (imiglucer-
ase), although symptomatic patients with mild to moderate
type 1 Gaucher disease for whom enzyme replacement
therapy (ERT) is not an option may also be treated by
substrate reduction therapy (SRT) with miglustat. To
determine whether the sequential use of both ERT and
SRT may provide additional benefits, we compared the
relative pharmacodynamic efficacies of separate and se-
quential therapies in a murine model of Gaucher disease
(D409V/null). As expected, ERT with recombinant gluco-
cerebrosidase was effective in reducing the burden of GL-1
storage in the liver, spleen, and lung of 3-month-old
Gaucher mice. SRT using a novel inhibitor of glucosylcer-
amide synthase (Genz-112638) was also effective, albeit to
a lesser degree than ERT. Animals administered recombi-
nant glucocerebrosidase and then Genz-112638 showed the
lowest levels of GL-1 in all the visceral organs and a
reduced number of Gaucher cells in the liver. This was
likely because the additional deployment of SRT following
enzyme therapy slowed the rate of reaccumulation of GL-1
in the affected organs. Hence, in patients whose disease has
been stabilized by intravenously administered recombinant
glucocerebrosidase, orally administered SRT with Genz-
112638 could potentially be used as a convenient mainte-
nance therapy. In patients naïve to treatment, ERT followed
by SRT could potentially accelerate clearance of the
offending substrate.
Abbreviations
CNS Central nervous system
ERT Enzyme replacement therapy
ESI/MS Electrospray ionization mass spectrometry
GD Gaucher disease
GL-1 Glucosylceramide
H&E Hematoxylin and eosin
HPLC High-performance liquid chromatography
NB-DNJ N-butyl deoxynojirimycin
SRT Substrate reduction therapy
Introduction
Gaucher disease (GD), the most common glycosphingolipid
storage disorder, is caused by a deficiency of glucocerebro-
sidase activity (Brady et al. 1966; Beutler and Grabowski
2001). This results in abnormal accumulation of glucosylcer-
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amide (GL-1) in lysosomes of cells from the monocytic/
macrophage system and consequent derangement of normal
cellular function. Patients can present with a variety of
clinical manifestations, including hepatosplenomegaly,
thrombocytopenia, anemia, bone disease, pulmonary hyper-
tension and, in more severe cases, central nervous system
(CNS) disease. Traditionally, GD patients who have no CNS
involvement are classified as having type 1 GD, whereas
those exhibiting CNS manifestations are categorized as
having neuronopathic GD (type 2 or 3, depending on rate
of progression).
Patients with GD are managed principally by enzyme
replacement therapy (ERT) with recombinant glucocerebrosi-
dase, (imiglucerase, Cerezyme®) (Weinreb et al. 2002;
Grabowski et al. 2009). Imiglucerase improves the visceral,
hematological, and skeletal manifestations of patients with
type 1 GD but not the CNS manifestations associated with
the neuronopathic forms due to the limited ability of the
enzyme to traverse the blood–brain barrier. An alternative
treatment for adult patients with mild to moderate forms of
type 1 GD for whom enzyme replacement therapy is not a
therapeutic option is substrate reduction therapy (SRT) using
N-butyldeoxynojirimycin (NB-DNJ) (miglustat, Zavesca®),
which inhibits GL-1 synthase, the enzyme that catalyzes the
synthesis of GL-1 (Platt et al. 1997; Cox et al. 2003).
However, the responses to therapy with miglustat are
reportedly slower and less robust than with imiglucerase
(Elstein et al. 2004), and treatment can be associated with
adverse side effects (Pastores et al. 2005; Hollak et al. 2009).
In addition to these treatments, a number of other treatment
approaches are under consideration for development in the
management of GD. An example is the pharmacological
chaperoning approach that seeks to promote the folding and
trafficking of mutant enzymes to the lysosomal compartment
(Steet et al. 2006; Lieberman et al. 2007; Yu et al. 2007).
Small-molecule drugs such as isofagomine that may be acting
as noncovalent active site inhibitors purportedly harbor these
characteristics and can facilitate increased enzyme levels in
lysosomes. Potentially complementing this strategy may be
the deployment of so-called proteostasis regulators to enhance
the concentration of folded mutant enzymes in the endoplas-
mic reticulum (Mu et al. 2008). Emerging technologies such
as gene augmentation therapy (McEachern et al. 2006) and
transplantation of gene-modified hematopoietic stem cells
(Enquist et al. 2006) represent yet other and perhaps more
transformative approaches to addressing this disease. Howev-
er, these technologies are still at an early and formative stage
of development. Finally, there are also efforts aimed at
generating biosimilar versions of the approved recombinant
enzyme using different expression systems (Elbein et al. 1990;
Shaaltiel et al. 2007). Whereas these may offer some
advantages in manufacturing, it is unlikely that they will
provide any improvements in efficacy (van Patten et al. 2007).
The continuing efforts to identify and develop novel
therapeutic approaches for GD are borne of the desire to
improve upon the current clinical practice. Included among
these is a desire to treat CNS disease, as well as improve
therapeutic response in bone and lung. (Futerman et al. 2004;
Wraith 2006; Mehta 2008). ERT also engenders production
of antibodies to the administered enzyme in a small number
of patients (∼15%), which can increase the risk of
hypersensitivity reactions, although such reactions are rare
in GD patients (Starzyk et al. 2007). Furthermore, as most
GD patients are treated by intravenously administered
enzyme infusions biweekly, therapies that can reduce
dependence on enzyme administrations could lessen the
burden of treatment as well as the incidence of infusion-
associated reactions.
In an attempt to address some of these issues, we examined
the relative pharmacodynamic efficacies of following ERT
(using recombinant glucocerebrosidase) with a novel drug for
SRT ( (Genz-112638), in a GD mouse model. The potential of
this sequential treatment approach to provide improvement
over that attained by the respective monotherapies was
highlighted in Sandhoff disease mice, a model for another
lysosomal storage disorder (Jeyakumar et al. 2005). However,
a recent clinical study in type 1 GD patients using SRT
(miglustat) and ERT (imiglucerase) showed that the treat-
ments were not additive, possibly because of partial inhibition
of glucocerebrosidase by miglustat. It did suggest that SRT
may offer an approach to facilitate maintenance therapy in
patients who had been stabilized by imiglucerase (Elstein et
al. 2007). The deployment of some small-molecule drugs,
such as NB-DNJ, with potential to cross the blood–brain
barrier, may also address CNS pathology. Finally, others and
we have shown that inhibitors of GL-1 synthase such as
Genz-112638 (Zhao et al. 2007) and MZ21 (Aerts et al.
2007) may have the added benefit of treating insulin
resistance shown to be associated with some GD patients
(Langeveld et al. 2008). Previously, we reported that Genz-
112638 is effective in addressing visceral disease in a GD
mouse model (D409V/null) (Xu et al. 2003; McEachern et al.
2007). Genz-112638 demonstrates a higher degree of
specificity for GL-1 synthase than does NB-DNJ, thereby
offering the potential for improved efficacy and fewer side
effects. Here, we extended the studies in this murine model to
include the use of this effector of SRT following infusions of
recombinant glucocerebrosidase.
Methods
Animal studies
Procedures involving animals were reviewed and approved
by the Institutional Animal Care and Use Committee
282 J Inherit Metab Dis (2010) 33:281–289
(IACUC) at Genzyme Corporation following the guidelines
issued by the Association for Assessment and Accreditation
of Laboratory Animal Care (AAALAC). The Gaucher
mouse (D409V/null) is a model of type 1 GD exhibiting
accumulation of GL-1 in liver, spleen, and lungs but
lacking bone or brain pathology (Xu et al. 2003). Animals
of both sexes were placed on study at 3 months of age, as
previous experiments had indicated that there was no
difference in response between males and females to
recombinant glucocerebrosidase or Genz-112638. The
investigational drug, Genz-112638, is an analog of EtDo-
P4 (ethylenedioxy-1-phenylpalmitoylamino-3-pyrrolidino-
1-propanol) described initially by Shayman and colleagues
(Inokuchi and Radin 1987; Lee et al. 1999). The study had
six groups of mice, with group A being sacrificed after
2 weeks to provide baseline levels of tissue GL-1. Groups
B, C, and D all received intravenously administered
infusions of 10 mg/kg recombinant human glucocerebrosi-
dase synthesized in Chinese Hamster Ovary (CHO) cells
(Genzyme Corp., Cambridge, MA, USA) (10 mg/kg) via a
tail-vein (100 µl) every 2 days for a total of eight injections.
Group B was sacrificed at the end of this regimen (at the
same time as group A) to provide enzyme-reduced levels of
tissue GL-1 immediately following treatment. Group C
received no further treatment and was sacrificed 12 weeks
after the start of the study to provide a measure of GL-1
reaccumulation. Groups D and E were both fed Genz-
112638 (Genzyme) as a component of the pellet-food diet,
with daily dosing starting the day after the last enzyme dose
(given to group D). The drug was formulated at 0.075% (w/
w) in standard 5053 mouse chow (TestDiet, Richmond, IN,
USA) and provided ad libitum. This formulation provided
150 mg/kg of Genz-112638 per day in a 25-g mouse eating
5 g of food per day. The dose of Genz-112638 was selected
based on earlier studies (McEachern et al. 2007). Group F
received no treatment and was sacrificed along with groups
C, D, and E, 12 weeks after the start of the study. Food
consumption and mouse weights were monitored three
times per week to determine drug intake and the potential
impact of the drug on overall health. Animals were killed
by carbon dioxide inhalation and their tissues harvested
immediately. Half of each tissue was snap frozen on dry ice
and stored at –80°C until ready for further processing. The
other half was processed for histological analysis.
Quantitation of tissue glucosylceramide levels
GL-1 levels were quantified by mass spectrometry as
described previously (McEachern et al. 2006); Doering et
al. 1999). A known mass of tissue was homogenized in 2:1
(v/v) chloroform:methanol and incubated at 37°C for
15 min. Samples were centrifuged, and the supernatants
were extracted with 0.2 volumes of water overnight at 4°C.
The samples were centrifuged, the aqueous phase was
discarded, and the organic phase was dried down to a film
under nitrogen. For electrospray ionization mass spectrom-
etry (ESI/MS) analysis, tissue samples were reconstituted to
the equivalent of 50 ng original tissue weight in 1 ml
chloroform:methanol (2:1, v/v) and vortexed for 5 min.
Aliquots (40 µl) of each sample were delivered to Waters
total recovery vials, and 50 µl of a 10 µg/ml d3-C16-GL-1
internal standard (Matreya, Inc., Pleasant Gap, PA, USA)
was added. Samples were dried under nitrogen and
reconstituted with 200 µl of 1:4 (v/v) dimethylsulfoxide
(DMSO):methanol. ESI/MS analysis of GL-1s of different
carbon chain lengths was performed on a Waters alliance
high-performance liquid chromatography (HPLC) (Separa-
tion Module 2695) coupled to a Micromass Quattro Micro
system equipped with an electrospray ion source. Lipid
extract samples (20 μl) were injected onto a C8 column
(4 ml×3 mm i.d; Phenomenex, Torrance, CA, USA) at
45°C and eluted with a gradient of 50–100% acetonitrile
(2 mM ammonium acetate, 0.1% formic acid) at 0.5 ml/min.
The first 0.5 min was held at 50% organic and then quickly
switched to 100% for the final 3.5 min. The source
temperature was held constant at 150°C, and nitrogen was
used as the desolvation gas at a flow rate of 670 L/h. The
capillary voltage was maintained at 3.80 kV with a cone
voltage of 23, and the dwell time for each ion species was
100 ms. Spectra were acquired by the multiple reaction
monitoring (MRM) mode to monitor eight dominant iso-
forms (C16:0, C18:0, C20:0, C22:1, C22:0, C22:1-OH,
C24:1, and C24:0). Quantitation of GL-1 was based on the
sum of these eight isoforms relative to the internal standard,
with a calibration curve ranging from 0.1 to 10 µg/ml.
Histology
For histological analysis, tissues were fixed in zinc formalin
(Electron Microscopy Sciences, Hatfield, PA, USA) at
room temperature for 24 h, then stored in phosphate-
buffered saline (PBS) at 4°C until ready for further
processing. All samples were dehydrated in ethanol, cleared
in xylenes, infiltrated, and embedded in Surgipath R
paraffin (Surgipath, Richmond, IL, USA). Five-micron
sections were cut using a rotary microtome and dried in a
60°C oven prior to staining. Sections were deparaffinized in
Hemo-De (Scientific Safety Solvents, Keller, TX, USA)
and rehydrated in descending concentrations of ethanol
followed by a wash with PBS. The sections were stained
with hematoxylin and eosin (H&E) and labeled using a rat
anti-mouse CD68 monoclonal antibody (Serotec, Raleigh,
NC, USA) to identify macrophages. After washing for
5 min in PBS, the slides were dehydrated in ethanol and
cleared in Hemo-De prior to mounting with SHUR/
Mount™ coverglass mounting medium (TBS, Durham,
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NC, USA). The percent area of CD68 immunopositivity in
the liver was quantified using MetaMorph (MDS Analytical
Technologies, Toronto, Canada) analysis of ten separate
400× images per tissue section. A board certified veterinary
pathologist blinded to group designation examined all
sections.
Results
Dosing regimen of glucocerebrosidase for debulking
accumulated GL-1 in the liver, spleen, and lung
of 3-month-old Gaucher mice
To investigate the relative merits of sequential therapy and
monotherapy with enzyme (recombinant glucocerebrosi-
dase) or substrate reduction (Genz-112638), we first
determined the enzyme regimen that maximally depleted
GL-1 levels in the visceral organs of Gaucher mice. Three-
month-old Gaucher mice (D409V/null) were intravenously
administered two, four, or eight doses of 10 mg/kg
recombinant human glucocerebrosidase. The mice treated
with two or four doses of the enzyme received drug
infusions every 3 days; those treated with eight doses
received the enzyme every 2 days. The use of a shorter time
interval between infusions in animals that received eight
treatments was designed to minimize the potential impact of
any immune response to the administered human enzyme
on efficacy. The animals were killed 7 days following the
last enzyme infusion, and the amount of GL-1 remaining in
their livers, spleens, and lungs was measured.
Treatment with two doses of glucocerebrosidase reduced
the levels of GL-1 in the liver by 50% (Fig. 1). Increasing
the number of enzyme infusions to four or eight, as
expected, reduced liver GL-1 levels to a greater extent (by
approximately 75%). The less than complete lowering of
GL-1 levels, even with eight doses, is consistent with the
experience in Gaucher patients where hepatosplenomegaly
is reduced only after an extended period of treatment
(Grabowski et al. 1995). The substrate levels in the spleens
of Gaucher mice were more refractory to enzyme treatment.
Administration of two doses of glucocerebrosidase did not
significantly alter GL-1 levels from those noted in untreated
controls (Fig. 1). Increasing the number of enzyme
infusions to four or eight reduced splenic GL-1 levels by
about 50%. In the lung, a reduction to approximately 60%
of untreated control was observed after eight doses. The
slightly lower extent of substrate reduction in the lung was
probably due to poorer accessibility of the infused enzyme
to the lipid-laden alveolar macrophages. The observation of
greater GL-1 clearance in the liver when compared with the
spleen and lung likely reflects the biodistribution of the
enzyme following systemic infusion (van Patten et al.
2007). Based on these results, the treatment regimen
consisting of eight consecutive doses of 10 mg/kg gluco-
cerebrosidase administered at 2-day intervals was used for
subsequent studies.
Relative abilities of enzyme and substrate reduction therapy
to lower GL-1 levels in the liver of Gaucher mice
Cohorts of 3-month-old Gaucher mice were treated with
either recombinant glucocerebrosidase (Fig. 2, columns B
& C) or Genz-112638 (inhibitor of GL-1 synthase)
separately (Fig. 2, column E) or sequentially (Fig. 2,
column D). Mice in groups B, C, and D were given eight
doses of enzyme as described above (over a period of
2 weeks) to clear accumulated GL-1. Different groups were
then fed either regular chow or chow containing Genz-
112638 (150 mg/kg per day) for an additional 10 weeks,
with group F receiving no treatment and serving as the
control. Irrespective of the chow formulation, the mice ate
comparable amounts of food, and there were no discernible
differences in weight gain (data not shown). Administration
of Genz-112638 at the dose indicated was well tolerated,
with no notable effects on the mice. Approximately 80% of
the stored GL-1 levels were cleared from the liver
following 2 weeks of enzyme therapy alone (Fig. 2, column
B). When these animals were allowed to progress without
further treatment for 10 weeks, their liver GL-1 levels
increased, indicating that reaccumulation of the substrate
had occurred during the intervening period (Fig. 2, column
C). These levels were not significantly different from those
of untreated controls (Fig. 2, column F). However, if the
mice were treated first with enzyme for eight doses and
then with Genz-112638 in their food over a 10-week
Fig. 1 Effect of administering exogenous glucocerebrosidase on
glucosylceramide (GL-1) levels in liver, spleen and lung. Three-
month-old Gaucher mice were administered 10 mg/kg recombinant
glucocerebrosidase intravenously two, four, or eight times. The two-
and four-dose cohorts received the enzyme 3 days apart, and the group
treated with eight doses was injected 2 days apart. GL-1 levels in the
liver (squares), spleen (triangles), and lung (circle) were measured
7 days after the last injection. Data are expressed as means ± standard
error of the mean (SEM) (n=5)
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period, their liver GL-1 levels were significantly lower than
the untreated controls (Fig. 2, columns D & F). This result
suggests that the additional treatment with Genz-112638
slowed substrate reaccumulation. Interestingly, Gaucher
mice treated with Genz-112638 alone during the entire
study period (12 weeks) also showed lower GL-1 levels
(Fig. 2, column E) when compared with untreated, age-
matched controls (Fig. 2, column F), though the difference
was not statistically significant. The ability of SRT alone to
reduce GL-1 levels in this animal model is consistent with
our previous report (McEachern et al. 2007) and likely
reflects the fact that Gaucher mice (D409V/null) retain
residual enzymatic activity (Xu et al. 2003).
Relative abilities of enzyme and substrate reduction therapy
to lower GL-1 levels in the spleen of Gaucher mice
Treating 3-month-old Gaucher mice with recombinant
glucocerebrosidase alone for 2 weeks reduced splenic
GL-1 levels by approximately 60% (Fig. 3, column B).
When these animals were allowed to age for an additional
10 weeks without further intervention, the substrate levels
returned to those observed at the start of the study (Fig. 3,
column C) and were not significantly different from the
untreated control (Fig. 3, column F). This suggests that the
rate of reaccumulation of GL-1 in the spleen was higher
than in the liver. This supposition was also supported by the
observation of higher basal levels of the substrate in the
spleen (∼1,500 µg/g tissue; Fig. 3, column A) than in
the liver (∼500 µg/g tissue; Fig. 2, column A). Animals
treated with enzyme for eight doses and then with Genz-
112638 for the next 10 weeks showed the greatest reduction
in splenic GL-1 levels (Fig. 3, column D), and these were
significantly lower than those in the untreated control
spleens (Fig. 3, column F). This indicated that the
deployment of Genz-112638 not only delayed the reaccu-
mulation of substrate but also acted to further reduce the
burden of storage in this organ. It would appear that at least
in this instance, the net effect of the residual endogenous
enzyme and substrate reduction led to a further decline in
overall substrate levels. The observation of lower splenic
GL-1 levels in mice treated with Genz-112638 alone for
12 weeks (Fig. 3, column E) than in untreated controls
(Fig. 3, column F) is consistent with this notion, though the
difference was not significant. Hence, in mild type 1 GD
patients with residual enzyme activity, treatment with
imiglucerase followed by Genz-112638 could potentially
accelerate the rate and perhaps even increase the extent of
clearance of the offending substrate.
Relative abilities of enzyme and substrate reduction therapy
to lower GL-1 levels in the lung of Gaucher mice
As noted earlier, pulmonary GL-1 levels were least
effectively cleared by intravenous administration of recom-
binant glucocerebrosidase. Treatment of 3-month-old
Gaucher mice with enzyme for 2 weeks resulted in only a
30% reduction in substrate levels in the lung (Fig. 4,
Fig. 3 Efficacy of enzyme and substrate reduction therapies at
lowering glucosylceramide (GL-1) levels in the spleen of Gaucher
mice. Spleen GL-1 levels were measured in untreated 3-month-old
Gaucher mice (A) and following 2 weeks of treatment with
recombinant glucocerebrosidase (B). Mice treated with recombinant
glucocerebrosidase were analyzed 10 weeks later without further
treatment (C) or after therapy with glucosylceramide synthase inhibitor
(Genz-112638) (D). GL-1 levels in the spleen of mice administered
Genz-112638 alone for the entire period of study (E) and in untreated,
age-matched controls (F) are also shown. Data are expressed as means ±
standard error of the mean (SEM) (n=5). Statistical significance was
determined using the unpaired t test
Fig. 2 Efficacy of enzyme and substrate reduction therapies at
lowering glucosylceramide (GL-1) levels in the liver of Gaucher
mice. Liver GL-1 levels were measured in untreated 3-month-old
Gaucher mice (A) and following 2 weeks of treatment with
recombinant glucocerebrosidase (B). Mice treated with recombinant
glucocerebrosidase were analyzed 10 weeks later without further
treatment (C) or after therapy with glucosylceramide synthase
inhibitor (Genz-112638) (D). GL-1 levels in the liver of mice
administered Genz-112638 alone for the entire study period (E) and
in untreated, age-matched controls (F) are also shown. Data are
expressed as means ± standard error of the mean (SEM) (n=5).
Statistical significance was determined using the unpaired t test
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column B). The cohort of animals fed normal chow for the
ensuing 10 weeks showed, as expected, reaccumulation of
GL-1 to untreated levels (Fig. 4, column C & F). In
contrast, animals fed chow containing Genz-112638 over
the same intervening period showed a reduction in substrate
levels to below those administered enzyme alone (Fig. 4,
column D) and were significantly lower than those in the
untreated controls (Fig. 4, column F). Again, this suggests
that in the lung, as in the spleen, the net effect of Genz-
112638 (in the presence of residual endogenous enzyme
activity) not only retarded the reaccumulation of GL-1 but
also acted to further reduce it to below starting levels. As
with the other visceral organs, treatment with Genz-112638
alone was effective in lowering pulmonary GL-1 levels
(Fig. 4, column E) when compared with untreated controls
(Fig. 4, column F).
Histopathological analysis of the liver of Gaucher mice
after enzyme and substrate reduction treatment
To visualize the effects of the different therapeutic regimens
in the liver, tissue sections were stained for CD68, a
macrophage marker. Analysis of liver sections from
untreated 3-month-old Gaucher mice showed the presence
of large numbers of lipid-engorged, CD68-positive Gaucher
cells (Fig. 5, panel a) that remained largely unchanged
when analyzed 12 weeks later (Fig. 5, panel f). Consistent
with the biochemical data above, livers of animals
administered recombinant glucocerebrosidase over a period
of 2 weeks showed substantial clearance of the lipid in
these abnormal macrophages (Fig. 5, panel b). If these
animals were allowed to age an additional 10 weeks
without further treatment, there was evidence of reaccumu-
lation of GL-1 as indicated by the reemergence of Gaucher
cells (Fig. 5, panel c). However, this increase in Gaucher
cells was negated if the mice were given substrate reduction
therapy with Genz-112638 over the same intervening
period (Fig. 5, panel d). As noted earlier, Gaucher mice
that received Genz-112638 alone also showed reduced
accumulation of the substrate (Fig. 5, panel e), although not
to the same degree as those that received sequential
treatment with recombinant glucocerebrosidase followed
by Genz-112638. The extent of CD68-positive staining on
the various sections was also quantified using MetaMorph
software (Fig. 6). The degree of staining in these sections
mirrored the amounts of liver GL-1 levels determined
biochemically (Fig. 2), further supporting suggestions on
the relative merits of the different treatment regimens.
Discussion
Extensive clinical experience with ERT using recombinant
glucocerebrosidase (alglucerase or imiglucerase) indicates
that this is an effective therapy for patients with type 1 GD.
Treatment with imiglucerase results in a reduction or
normalization of hepatosplenomegaly, a lower frequency
of bone pain and bone crises, and improvement in a variety
of hematological and biochemical biomarkers (Weinreb et
al. 2002; Grabowski et al. 2009; Charrow et al. 2004; de
Fost et al. 2006). Studies to optimize dosing of ERT for
type 1 GD and maximize patient convenience continue
(Grabowski et al. 2009; de Fost et al. 2006; Weinreb et al.
2008; Zimran et al. 2009; Kishnani et al. 2009). Whereas a
consensus has not yet been reached, it is apparent that
higher doses and more frequent infusions generally result in
more rapid reversal of several disease parameters (Grabowski
et al. 2009).
SRT with miglustat is also available to type 1 GD
patients with mild to moderate disease for whom ERT is not
a therapeutic option. The SRT approach seeks to retard
synthesis of glycosphingolipids to rates at which the
residual enzymatic activity is able to catabolize stored and
incoming GL-1 (Platt et al. 1997; Inokuchi and Radin
1987). Clinical studies indicate that in addition to offering
the convenience of oral therapy, SRT could also reduce the
burden of GL-1 storage, with a resultant improvement in
disease manifestations, albeit over a longer period of
treatment than with ERT (Cox et al. 2003; Elstein et al.
2007; Pastores et al. 2009). Moreover, a study of patients
treated by ERT and then switched to SRT with miglustat
suggests that the latter might be deployed in the context of
Fig. 4 Efficacy of enzyme and substrate reduction therapies at
lowering glucosylceramide levels in the lung of Gaucher mice. Lung
glucosylceramide (GL-1) levels were measured in untreated 3-month-
old Gaucher mice (A) and following 2 weeks of treatment with
recombinant glucocerebrosidase (B). Mice treated with recombinant
glucocerebrosidase were analyzed 10 weeks later without further
treatment (C) or after therapy with glucosylceramide synthase
inhibitor (Genz-112638) (D). GL-1 levels in the lung of mice
administered Genz-112638 alone for the entire study period (E) and
in untreated, age-matched controls (F) are also shown. Data are
expressed as means ± standard error of the mean (SEM) (n=5).
Statistical significance was determined using the unpaired t test
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maintenance therapy for GD patients, particularly those
whose disease has been stabilized by ERT (Elstein et al.
2007; Giraldo et al. 2006). However, a combination of both
ERT with imiglucerase and SRT with miglustat reportedly
did not provide additional benefits (Elstein et al. 2007),
possibly due to nonspecific inhibition of glucocerebrosidase
by NB-DNJ. The premise for the study presented here was
predicated on the notion that because the two therapeutic
strategies have dissimilar modes of actions, they might be
additive. Evidence of different therapies showing benefit
were illustrated in an animal model of Sandhoff disease,
another lysosomal storage disorder, whereby a combination
of bone marrow transplantation (to provide enzyme) and
SRT (NB-DNJ) was more effective than either treatment
alone (Jeyakumar et al. 2001). Moreover, as the biodis-
tribution and pharmacodynamics of a small-molecule drug
are different from enzyme, the hope was that SRT might
address diseased organs that were less amenable to ERT,
such as bone, lung, and even the central nervous system
(CNS).
Fig. 5 Immunohistochemical
staining of liver of Gaucher
mice following treatment with
enzyme (ERT) and substrate
reduction therapy (SRT). Liver
sections were stained with an
anti-CD68 antibody to visualize
macrophages. Sections shown
were from untreated 3-month-
old Gaucher mice (a),
3-month-old Gaucher mice
dosed with glucocerebrosidase
and analyzed after 2 weeks of
treatment (b), or 10 weeks later
(c). Liver of Gaucher mice
administered enzyme followed
by glucosylceramide synthase
inhibitor (Genz-112638) (d),
and from those that received
Genz-112638 alone (e), liver
of untreated Gaucher mice
at the end of the study
(12 weeks later) (f)
Fig. 6 The extent of CD68-positive staining on liver sections was
quantified using MetaMorph software. Levels in untreated 3-month-old
Gaucher liver (A) or following treatment with glucocerebrosidase (B).
Mice treated with enzyme and then analyzed 10 weeks later without
further therapeutic intervention (C) or after therapy with glucosylcer-
amide synthase inhibitor (Genz-112638) (D). Extent of staining in the
liver of Gaucher mice administered Genz-112638 alone (E) and in
untreated, age-matched control mice (F). The data was collated from an
analysis of ten 400× images per section from each mouse. Statistical
significance was determined using the unpaired t test
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Two small-molecule drugs, one approved (NB-DNJ) and
the other in phase 3 clinical testing (Genz-112638), have
been developed for SRT of type 1 GD. Both inhibit GL-1
synthase, the enzyme that catalyzes the first step in the
biosynthesis of glycosphingolipids. Genz-112638, an in-
vestigational drug, was developed with the goal of reducing
some of the purported off-target effects shown to be
associated with NB-DNJ, which could lead to gastrointes-
tinal distress, tremor, and peripheral neuropathy (Cox et al.
2003; Pastores et al. 2009). We reported previously that
Genz-112638 exhibits high potency and specificity at
inhibiting GL-1 synthase and is effective at reducing
lysosomal accumulation of GL-1 in a murine model of
GD (McEachern et al. 2007). We extended these studies to
ascertain the relative merits of its use after initial enzyme
administration in the same murine model. Although in the
original murine studies Genz-112638 was administered via
oral gavage, bridging studies have generated similar results
when the inhibitor was delivered as a component of the
chow.
The primary objective of the studies was to determine
whether introducing SRT after ERT could improve upon the
pharmacodynamic efficacy observed with either therapy
alone or maintain the efficacy observed with ERT alone. As
expected, treatment with either modality alone was effec-
tive in reducing substrate accumulation in all the visceral
organs tested. As such, they support the clinical findings
noted in type 1 GD patients. Moreover, there was a
sustained reduction of GL-1 levels observed in the visceral
organs of mice treated with Genz-112638 after prior
substrate clearance by ERT. Importantly, mice that received
sequential treatment with recombinant glucocerebrosidase
and Genz-112638 showed greater substrate clearance than
realized with either treatment alone. This would suggest
that the sequential use of the two therapeutic modalities was
additive. Hence, a sequential treatment approach may be
considered in instances where rapid debulking of accumu-
lated GL-1 is desirable, as may occur in adult type 1 GD
patients who are naïve to treatment. However, as noted
earlier, a study with sequential recombinant glucocerebro-
sidase (imiglucerase) and miglustat, albeit in a small
number of GD patients, showed no additional benefit
(Elstein et al. 2007). Hence, the translatability of these
observations in mice to humans is yet to be validated.
Moreover, as miglustat was associated with some side
effects in GD patients, a better understanding of whether
this was specifically associated with the drug or if this was
a class effect needs to be determined.
In summary, the data presented here demonstrate that in
mice, treatment with ERT using recombinant glucocerebrosi-
dase followed by SRTusing Genz-112638may be an effective
approach to managing the substrate that accumulates in the
visceral organs of nonneuropathic GD patients. These find-
ings support the design of a proposed phase 3 trial in humans
that will evaluate Genz-112638 in patients previously treated
with imiglucerase. During the execution of these studies,
another mouse model of GD that is more reflective of the
disease manifestations in patients was generated (Enquist et al.
2006). Additional testing of this treatment paradigm in the
more severely affected mouse model is warranted to further
ascertain the merits of this strategy. Moreover, as Genz-
112638 is an inhibitor of GL-1 synthase that initiates the
glycosphingolipid biosynthetic pathway, this treatment para-
digm may also be evaluated in other glycosphingolipid
storage diseases, such as Fabry disease.
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